De-escalating Therapy in Localized Diffuse Large B-Cell Lymphoma

Eliminating radiotherapy after immunochemotherapy did not affect outcomes in nonbulky, stage I–II disease.

The utility of combined-modality treatment for patients with localized diffuse large B-cell lymphoma (DLBCL) has been controversial. To examine this issue further, French investigators conducted a prospective randomized trial in which 334 newly diagnosed patients with nonbulky (<7 cm) stage I–II DLBCL based on positron emission tomography–computed tomography (PET/CT) imaging received immunochemotherapy with or without radiotherapy.

Patients with no modified International Prognostic Index (IPI) risk factors (stage, >I; age, >60; performance status, >0; elevated lactate dehydrogenase [LDH]) received four cycles of R-CHOP-14, whereas those with one or more risk factors received six cycles. Patients in each group were then randomized to receive …

Reviewing Author

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

De-escalating Therapy in Localized Diffuse Large B-Cell Lymphoma

Topics

Reviewing Author